At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
QLGN Qualigen Therapeutics, Inc.
Post-Mkt 12-10 18:32:10 EST
3.21
+0.00
0.00%
High3.21
Low3.21
Vol0.00
Open3.21
D1 Closing3.21
Amplitude0.00%
Mkt Cap16.56M
Tradable Cap6.52M
Total Shares5.16M
T/O1.18M
T/O Rate0.00%
Tradable Shares2.03M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Jia Yueting's investment in the listed company QLGN has been renamed to AIxCrypto and will engage in stock tokenization business
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: On November 20, QLGN, which is Strategically Invested in and Controlled by FFAI, will Begin Using its New Name, AIxCrypto, and will be Traded Under AIXC
Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 Strategy
Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?
Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.